Literature DB >> 33933849

Artesunate-induced ATG5-related autophagy enhances the cytotoxicity of NK92 cells on endometrial cancer cells via interactions between CD155 and CD226/TIGIT.

Jie Zhang1, Long Zhou1, Jiang-Dong Xiang1, Chun-Sheng Jin2, Ming-Qing Li3, Yin-Yan He4.   

Abstract

Uterine corpus endometrial carcinoma (UCEC) is the most prevalent gynecologic cancer in developed countries and lacks efficient therapeutic strategies. Artesunate (ART), a well-modified derivate of artemisinin, exerts potent anti-cancer effects apart from its classical anti-malaria feature. Autophagy is a universal double-edged process in cell survival, and CD155 is a novel immune checkpoint highly expressed in numerous cancers. However, the relationships among ART, autophagy, and CD155 remain unclear in UCEC. In this study, we discovered that ART not only inhibited proliferation and migration, promoted apoptosis, but also induced autophagy in UCEC cells. Meanwhile, ART-induced autophagy elevated the level of CD155 in UCEC cells, thereby enhancing the cytotoxicity of natural killer cell line (NK92) by modulating the interactions between CD155 and its receptors in NK92 cells via upregulation of co-stimulator CD226 and downregulation of co-inhibitor TIGIT. Additionally, ART regulated CD155 partially via ATG5, and knockdown of ATG5 dampened the expression of CD155 in UCEC cells, thus decreasing the cytotoxicity of NK92 cells. Therefore, this study demonstrated the dual anti-cancer effects of ART as it could induce cell-killing directly and indirectly, which provides novel insights into the anti-cancer mechanisms of ART on UCEC.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Artesunate; Autophagy; CD155; Endometrial cancer; NK cell

Mesh:

Substances:

Year:  2021        PMID: 33933849     DOI: 10.1016/j.intimp.2021.107705

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  4 in total

Review 1.  Update in TIGIT Immune-Checkpoint Role in Cancer.

Authors:  Tiziana Annese; Roberto Tamma; Domenico Ribatti
Journal:  Front Oncol       Date:  2022-05-17       Impact factor: 5.738

Review 2.  Artemisinin-Type Drugs in Tumor Cell Death: Mechanisms, Combination Treatment with Biologics and Nanoparticle Delivery.

Authors:  Xinyu Zhou; Fengzhi Suo; Kristina Haslinger; Wim J Quax
Journal:  Pharmaceutics       Date:  2022-02-10       Impact factor: 6.321

Review 3.  Harnessing autophagy to fight SARS-CoV-2: An update in view of recent drug development efforts.

Authors:  Theo Rein
Journal:  J Cell Biochem       Date:  2021-10-20       Impact factor: 4.480

Review 4.  Recent Advances in the Therapeutic Efficacy of Artesunate.

Authors:  Ngonidzashe Ruwizhi; Rejoice Bethusile Maseko; Blessing Atim Aderibigbe
Journal:  Pharmaceutics       Date:  2022-02-25       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.